Thomas Jefferson University

James Zangrilli

TitleAssoc Prof CHP
InstitutionThomas Jefferson University
DepartmentNursing - Undergraduate
Address1025 Walnut St.
Philadelphia PA 19107
Phone215-955-0887
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    K08HL003663     (ZANGRILLI, JAMES G)Jul 1, 1998 - Jun 30, 2004
    NIH
    MECHANISMS OF PROGRAMED CELL DEATH IN EOSINOPHILS
    Role: Principal Investigator
    R01HL076646     (HACZKU, ANGELA)Dec 15, 2004 - Nov 30, 2010
    NIH
    Regulation of Inflammation in Asthma by Fas Ligand
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Buchheit KM, Shaw D, Chupp G, Lehtimaki L, Heffler E, Finney-Hayward T, Zangrilli J, Kwiatek J, Siddiqui S, Roufosse F, Thamboo A, West N, Vichiendilokkul A, Hellings PW, Peters A, Howarth PH. Interleukin-5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils. Allergy. 2024 Oct; 79(10):2662-2679. PMID: 39359069.
      Citations:    
    2. Heaney LG, Perez de Llano L, Al-Ahmad M, Backer V, Busby J, Canonica GW, Christoff GC, Cosio BG, FitzGerald JM, Heffler E, Iwanaga T, Jackson DJ, Menzies-Gow AN, Papadopoulos NG, Papaioannou AI, Pfeffer PE, Popov TA, Porsbjerg CM, Rhee CK, Sadatsafavi M, Tohda Y, Wang E, Wechsler ME, Alacqua M, Altraja A, Bjermer L, Björnsdóttir US, Bourdin A, Brusselle GG, Buhl R, Costello RW, Hew M, Siyue MK, Lehmann S, Lehtimäki L, Peters M, Taillé C, Taube C, Tran TN, Zangrilli J, Bulathsinhala L, Carter VA, Chaudhry I, Eleangovan N, Hosseini N, Kerkhof M, Murray RB, Price CA, Price DB. Eosinophilic and non-eosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort. Chest. 2021 Apr 19. PMID: 33887242.
      Citations:    
    3. Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med. 2020 Dec 22. PMID: 33357499.
      Citations:    
    4. Jauhiainen A, Scheepers LEJM, Fuhlbrigge AL, Harrison T, Zangrilli J, Garcia Gil E, Gustafson P, Fagerås M, Da Silva CA. Impact of season and geography on CompEx Asthma: a composite end-point for exacerbations. ERJ Open Res. 2020 Oct; 6(4). PMID: 33123561.
      Citations:    
    5. FitzGerald JM, Tran TN, Alacqua M, Altraja A, Backer V, Bjermer L, Bjornsdottir U, Bourdin A, Brusselle G, Bulathsinhala L, Busby J, Canonica GW, Carter V, Chaudhry I, Cho YS, Christoff G, Cosio BG, Costello RW, Eleangovan N, Gibson PG, Heaney LG, Heffler E, Hew M, Hosseini N, Iwanaga T, Jackson DJ, Jones R, Koh MS, Le T, Lehtimäki L, Ludviksdottir D, Maitland-van der Zee AH, Menzies-Gow A, Murray RB, Papadopoulos NG, Perez-de-Llano L, Peters M, Pfeffer PE, Popov TA, Porsbjerg CM, Price CA, Rhee CK, Sadatsafavi M, Tohda Y, Wang E, Wechsler ME, Zangrilli J, Price DB. International severe asthma registry (ISAR): protocol for a global registry. BMC Med Res Methodol. 2020 Aug 14; 20(1):212. PMID: 32819285.
      Citations:    
    6. Tran TN, MacLachlan S, Hicks W, Liu J, Chung Y, Zangrilli J, Rubino A, Ganz ML. Oral Corticosteroid Treatment Patterns of Patients in the United States with Persistent Asthma. J Allergy Clin Immunol Pract. 2020 Jun 19. PMID: 32569754.
      Citations:    
    7. Jackson DJ, Korn S, Mathur SK, Barker P, Meka VG, Martin UJ, Zangrilli JG. Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab. Drug Saf. 2020 May; 43(5):409-425. PMID: 32242310.
      Citations:    
    8. Mathur SK, Modena BD, Coumou H, Barker P, Kreindler JL, Zangrilli JG. Postbronchodilator Lung Function Improvements with Benralizumab for Patients with Severe Asthma. Allergy. 2020 Jan 10. PMID: 31925789.
      Citations:    
    9. Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN, Busby J, Jackson DJ, Pfeffer PE, Rhee CK, Cho YS, Canonica GW, Heffler E, Gibson PG, Hew M, Peters M, Harvey ES, Alacqua M, Zangrilli J, Bulathsinhala L, Carter VA, Chaudhry I, Eleangovan N, Hosseini N, Murray RB, Price DB. Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry. Chest. 2019 Nov 27. PMID: 31785254.
      Citations:    
    10. Chipps BE, Hirsch I, Trudo F, Alacqua M, Zangrilli JG. Benralizumab Efficacy for Patients with Fixed Airflow Obstruction and Severe, Uncontrolled Eosinophilic Asthma. Ann Allergy Asthma Immunol. 2019 Oct 15. PMID: 31626906.
      Citations:    
    11. Park HS, Lee SH, Lee SY, Kim MK, Lee BJ, Werkström V, Barker P, Zangrilli JG. Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma. Allergy Asthma Immunol Res. 2019 Jul; 11(4):508-518. PMID: 31172719.
      Citations:    
    12. Chupp G, Lugogo NL, Kline JN, Ferguson GT, Hirsch I, Goldman M, Zangrilli JG, Trudo F. Rapid Onset of Effect of Benralizumab on Morning Peak Expiratory Flow in Severe, Uncontrolled Asthma. Ann Allergy Asthma Immunol. 2019 Feb 22. PMID: 30802500.
      Citations:    
    13. Bleecker ER, Wechsler ME, FitzGerald JM, Menzies-Gow A, Wu Y, Hirsch I, Goldman M, Newbold P, Zangrilli JG. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018 Oct; 52(4). PMID: 30139780.
      Citations:    
    14. Murphy K, Jacobs J, Bjermer L, Fahrenholz JM, Shalit Y, Garin M, Zangrilli J, Castro M. Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2017 Nov - Dec; 5(6):1572-1581.e3. PMID: 29122156.
      Citations:    
    15. FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, Newbold P, Goldman M. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018 Jan; 6(1):51-64. PMID: 28919200.
      Citations:    
    16. Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies. Curr Med Res Opin. 2017 Jun 23; 1-26. PMID: 28644104.
      Citations:    
    17. Brusselle G, Germinaro M, Weiss S, Zangrilli J. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulm Pharmacol Ther. 2017 Apr; 43:39-45. PMID: 28159511.
      Citations:    
    18. Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. Chest. 2016 Oct; 150(4):789-798. PMID: 27056586.
      Citations:    
    19. Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts. Chest. 2016 Oct; 150(4):799-810. PMID: 27018175.
      Citations:    
    20. Wang Y, Miwa T, Ducka-Kokalari B, Redai IG, Sato S, Gullipalli D, Zangrilli JG, Haczku A, Song WC. Properdin Contributes to Allergic Airway Inflammation through Local C3a Generation. J Immunol. 2015 Aug 1; 195(3):1171-81. PMID: 26116506.
      Citations:    
    21. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O'Brien C, Korn S. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015 May; 3(5):355-66. PMID: 25736990.
      Citations:    
    22. Tashkin DP, Chipps BE, Trudo F, Zangrilli JG. Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses. J Asthma. 2014 Aug; 51(6):603-9. PMID: 24524222.
      Citations:    
    23. Murphy KR, Uryniak T, Martin UJ, Zangrilli J. The effect of budesonide/formoterol pressurized metered-dose inhaler on predefined criteria for worsening asthma in four different patient populations with asthma. Drugs R D. 2012 Mar 1; 12(1):9-14. PMID: 22329608.
      Citations:    
    24. Zangrilli J, Mansfield LE, Uryniak T, O'Brien CD. Efficacy of budesonide/formoterol pressurized metered-dose inhaler versus budesonide pressurized metered-dose inhaler alone in Hispanic adults and adolescents with asthma: a randomized, controlled trial. Ann Allergy Asthma Immunol. 2011 Sep; 107(3):258-65.e2. PMID: 21875546.
      Citations:    
    25. Salerno D, Gushue G, Gupta N, Zangrilli J. Decades later, a new complication. Am J Med. 2008 Apr; 121(4):293-4. PMID: 18374687.
      Citations:    
    26. Segal M, Niazi S, Simons MP, Galati SA, Zangrilli JG. Bid activation during induction of extrinsic and intrinsic apoptosis in eosinophils. Immunol Cell Biol. 2007 Oct; 85(7):518-24. PMID: 17549073.
      Citations:    
    27. Hastie AT, Wu M, Foster GC, Hawkins GA, Batra V, Rybinski KA, Cirelli R, Zangrilli JG, Peters SP. Alterations in vasodilator-stimulated phosphoprotein (VASP) phosphorylation: associations with asthmatic phenotype, airway inflammation and beta2-agonist use. Respir Res. 2006; 7:25. PMID: 16480498.
      Citations:    
    28. Weinberg NM, Zwas DR, Owen AN, Zangrilli JG, Van Tassell P. Left ventricular intracardiac metastatic germ cell tumor presenting with hemorrhagic cerebrovascular event. J Am Soc Echocardiogr. 2004 Oct; 17(10):1080-3. PMID: 15452476.
      Citations:    
    29. Robertson NM, Rosemiller M, Lindemeyer RG, Steplewski A, Zangrilli JG, Litwack G. TRAIL in the airways. Vitam Horm. 2004; 67:149-67. PMID: 15110176.
      Citations:    
    30. Niazi S, Robertson NM, Agrawal A, Hastie AT, Peters SP, Zangrilli J. Overlap between death receptor and non-receptor-mediated mechanisms during apoptosis in human eosinophils. Chest. 2003 Mar; 123(3 Suppl):345S. PMID: 12628970.
      Citations:    
    31. Hastie AT, Batra V, Khurana S, Carpenter KA, Cirelli R, Zangrilli JG, Peters SP. Modulation of vasodilator-stimulated phosphoprotein in vivo in human epithelial cells by segmental allergen challenge and beta2-agonist therapy. Chest. 2003 Mar; 123(3 Suppl):377S. PMID: 12628994.
      Citations:    
    32. Batra V, Khurana S, Musani AI, Hastie AT, Carpenter KA, Zangrilli JG, Peters SP. Concentration of cytokines and growth factors in BAL fluid after allergen challenge in asthmatics and their effect on alpha-smooth muscle actin and collagen III synthesis by human lung fibroblasts. Chest. 2003 Mar; 123(3 Suppl):398S-9S. PMID: 12629001.
      Citations:    
    33. Robertson NM, Zangrilli JG, Steplewski A, Hastie A, Lindemeyer RG, Planeta MA, Smith MK, Innocent N, Musani A, Pascual R, Peters S, Litwack G. Differential expression of TRAIL and TRAIL receptors in allergic asthmatics following segmental antigen challenge: evidence for a role of TRAIL in eosinophil survival. J Immunol. 2002 Nov 15; 169(10):5986-96. PMID: 12421985.
      Citations:    
    34. Niazi S, Batra V, Zangrilli JG. Atypical mycobacterial osteomyelitis in a non-AIDS patient. Conn Med. 2002 Jul; 66(7):387-9. PMID: 12181861.
      Citations:    
    35. Zangrilli JG. Regulation of eosinophil viability by cytokines. Am J Respir Cell Mol Biol. 2002 Apr; 26(4):388-90. PMID: 11919073.
      Citations:    
    36. Loza MJ, Peters SP, Zangrilli JG, Perussia B. Distinction between IL-13+ and IFN-gamma+ natural killer cells and regulation of their pool size by IL-4. Eur J Immunol. 2002 Feb; 32(2):413-23. PMID: 11813160.
      Citations:    
    37. Hastie AT, Kraft WK, Nyce KB, Zangrilli JG, Musani AI, Fish JE, Peters SP. Asthmatic epithelial cell proliferation and stimulation of collagen production: human asthmatic epithelial cells stimulate collagen type III production by human lung myofibroblasts after segmental allergen challenge. Am J Respir Crit Care Med. 2002 Jan 15; 165(2):266-72. PMID: 11790666.
      Citations:    
    Zangrilli's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (123)
    Explore
    _
    Co-Authors (4)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _